Frank D. Heuszel, the Chief Executive Officer of Impact Biomedical Inc. (NASDAQ:IBO), recently purchased 500 shares of the company's common stock. The transaction, which took place on December 5, 2024, was valued at approximately $1,128, with each share priced at $2.2578. The purchase comes as the stock has experienced a significant 15% decline over the past week, according to InvestingPro data. Following this acquisition, Heuszel's direct ownership stands at 97,344 shares. This move reflects a modest increase in his holdings within the pharmaceutical preparations sector, where Impact Biomedical operates. With a market capitalization of $24.6 million and a current ratio of 2.79, InvestingPro analysis indicates the company maintains strong liquidity. The stock currently trades below its Fair Value, with additional insights available through InvestingPro's comprehensive financial health assessment.
"In other recent news, Impact BioMedical has made significant strides in both patent acquisition and executive appointments. The company secured a new U.S. patent for an insect repelling composition, expanding its 3F™ technology platform. U.S. Patent No. 11,985,973, set to expire in February 2039, covers plant-based compositions that can potentially reduce insect landings and bites. This technology, inhibiting the olfactory receptors of insects, could be incorporated into products like detergents, shampoos, or lotions to repel insects. This development follows the previously granted U.S. Patent No. 11,246,310, with an expiry in April 2040.
In parallel to these patent advancements, Impact BioMedical announced the formation of a new executive leadership team. The team comprises Frank D. Heuszel as CEO, Mark Suseck as COO, and Todd Macko as CFO, all bringing extensive experience in their respective fields. The company anticipates this leadership assembly will guide them through a period of innovation and expansion. These recent developments are seen as key steps in positioning Impact BioMedical for sustained success in the healthcare sector."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.